Blog

Discover the latest in medical marketing, key personnel shifts, and buzzworthy industry updates this week.

Explore the latest in medical marketing, key personnel shifts, and buzzing industry conversations in this week’s essential update.

Weekly semaglutide reduces major cardiovascular events by 20% in overweight adults without diabetes but with pre-existing heart conditions.

EVOLUTION study: Evobrutinib falls short in primary endpoint for relapsing MS versus Sanofi’s Aubagio.

Over half of pharmaceutical professionals prioritize healthcare provider insights for strategic engagement in 2024.

Study suggests Medical Science Liaisons (MSLs) eclipse sales reps in driving healthcare provider engagement, signaling a potential ascendancy for medical affairs.

Pending approval, V116 aims to protect seniors, positioning as a rival to Pfizer’s Prevnar 20 in the pneumococcal vaccine market.

Lilly and Prism’s $600+ million collaboration aims to identify new, easily targetable small-molecule drug candidates.

Kite Pharma expands its partnership with Arcellx, acquiring ACLX-001, an innovative BCMA-directed CAR-T therapy for treating multiple myeloma.

Merck acquires Caraway Therapeutics’ trio of preclinical Parkinson’s and rare disease treatments in a $610 million agreement.